| abstract |
In some aspects, the present disclosure relates to a method of treating chronic graft versus host disease (cGVHD). In some embodiments, the method comprises administering an EZH2 inhibitor, Bcl6 inhibitor and / or BRD4 inhibitor to a subject in need thereof. The present disclosure relates, at least in part, to a zeste homolog 2 enhancer (EZH2) inhibitor, a B cell lymphoma 6 protein (Bcl6) inhibitor and / or a bromodomain-containing protein 4 (BRD4) inhibitor for chronic graft-versus-host disease. Based on the discovery that it can be used to treat (cGVHD). |